Navigation Links
Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
Date:5/18/2009

plicable law.

Conference Call

Simcere Pharmaceutical Group will host a conference call to discuss the Company's results for the first quarter 2009 on Tuesday, May 19, at 8 a.m. Eastern Time (Tuesday, May 19, at 8 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for first quarter 2009 and to answer questions.

    To access the conference call, please dial:

     United States toll-free dial-in number: +1 800 659 2056
     International dial-in number:           +1 617 614 2714
     North China toll-free dial-in number:   +86 10 800 152 1490
     South China toll-free dial-in number:   +86 10 800 130 0399
     Hong Kong dial-in number:               +852 3002 1672

Please ask to be connected to Simcere's Q1 2009 earnings call and provide the following passcode: 25770430. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the Company's web site at http://www.simcere.com .

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1 888 286 8010

     United States dial-in number:           +1 617 801 6888

The passcode for replay participants is: 21293840. The telephone replay also will be archived on the "Investor Relations" section of the Company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its stra
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009
2. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
3. Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009
4. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
5. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
6. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
7. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
8. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
9. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
10. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
11. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering Manager ... Orange County, Texas area from future storm surge flooding, such as occurred in Hurricane ... levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental needs ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2
... 2011 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... financial results for the fourth quarter and the ... highlighted important commercial, regulatory and clinical development progress ... operational guidance for 2011. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO) ...
... February 9, 2011 Engineers and scientists collaborating at ... demonstrated the world,s first programmable nanoprocessor. The groundbreaking ... in the journal Nature , represents a significant ... can be assembled from synthesized nanometer-scale components. It ...
... The New England Journal of Medicine (NEJM) ... plus best supportive care (BSC) more than doubled progression-free ... plus BSC in patients with advanced pancreatic neuroendocrine tumors ... (RAD001 In Advanced Neuroendocrine Tumors), were first presented last ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 2Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 3Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 4Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 5Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 6Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 7Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 8Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 9Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011 10Researchers at Harvard and MITRE produce world's first programmable nanoprocessor 2Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 2Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 3Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 4Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 5Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 6Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 7Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 8Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 9Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 10Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 11Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows 12
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... focus on forestsas opposed to the entire landscapecould ... poor in developing countries, said a Nairobi-based agroforestry ... forest degradation is driven by forces outside forests, ... land uses that involve the whole landscape, not ...
... This release is available in French . ... Laval, in collaboration with Nova Scotia Agricultural College, have discovered ... to double the lifespan of Christmas trees in homes. The ... scientific journal Trees . The researchers have identified ...
... Personality is not just a feature unique to humans ... have revealed that also brown trout have individual characters ... the Department of Zoology at the University of Gothenburg ... trout from watercourses on the west coast of Sweden. ...
Cached Biology News:Towards an efficient, effective and equitable REDD+ 2Towards an efficient, effective and equitable REDD+ 3Towards an efficient, effective and equitable REDD+ 4Researchers discover a way to delay Christmas tree needle loss 2
Taq DNA polymerase, 10,000U...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Request Info...
Biology Products: